Core Viewpoint - Anixa Biosciences has received approval for the non-proprietary name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant step towards its commercialization [1][2]. Group 1: Company Developments - The USAN Council approved the non-proprietary name for Anixa's CAR-T therapy, which follows prior approval from the WHO's INN Expert Committee, allowing for a globally recognized drug name [1][2]. - The company is focused on executing its ongoing Phase 1 trial of liraltagene autoleucel, in partnership with Moffitt Cancer Center, aimed at treating ovarian cancer [2][3]. - Liraltagene autoleucel is a novel CAR-T therapy that targets the follicle stimulating hormone receptor (FSHR), which is expressed on normal ovarian cells and certain cancer cells [3]. Group 2: Technology and Research - The CAR-T technology, known as chimeric endocrine receptor-T cell (CER-T) therapy, utilizes a natural ligand to bind to the FSHR receptor on tumor cells, differentiating it from traditional cell therapies [3]. - The ongoing Phase 1 trial is designed to evaluate safety, identify the maximum tolerated dose, and monitor clinical activity in adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [3]. Group 3: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4]. - The company also has a vaccine portfolio aimed at treating and preventing breast and ovarian cancer, developed in collaboration with Cleveland Clinic, which is entitled to royalties from these technologies [4]. - Anixa's business model involves partnerships with leading research institutions to explore and commercialize emerging technologies in cancer treatment [4].

Core Insights - Anixa Biosciences has completed the transfer of the Investigational New Drug application for its breast cancer vaccine from Cleveland Clinic, becoming the trial sponsor for its future development [1][2] - The company plans to advance the vaccine into a Phase 2 clinical trial after completing enrollment and observing encouraging immune response and safety data in the Phase 1 trial [2][4] - The breast cancer vaccine targets -lactalbumin, a protein that re-emerges in many forms of breast cancer, potentially offering therapeutic and preventive benefits [3] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company’s vaccine portfolio includes vaccines for breast and ovarian cancer, developed in collaboration with Cleveland Clinic, and aims to address various cancers by immunizing against "retired" proteins expressed in certain cancer forms [5] - Anixa's business model involves partnering with renowned research institutions to explore emerging technologies for further development and commercialization [5]

Core Insights - Anixa Biosciences has executed a data transfer agreement with Cleveland Clinic, marking a significant step in transferring the breast cancer vaccine clinical trial data and sponsorship to Anixa for future clinical development [1][2][4] Group 1: Clinical Development - Enrollment for the Phase 1 trial has been completed, showing encouraging immune response data, leading Anixa to advance the vaccine into a Phase 2 clinical trial [2] - The IND, currently sponsored by Cleveland Clinic, is in the process of being transferred to Anixa, allowing the company to assume full sponsorship [2][4] Group 2: Vaccine Technology - The breast cancer vaccine targets -lactalbumin, a protein typically expressed in breast tissue during lactation, which re-emerges in various forms of breast cancer [3] - By establishing an immune response against -lactalbumin-expressing cells, the vaccine may provide both therapeutic and preventive benefits for patients with tumors expressing this protein [3] Group 3: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company’s vaccine portfolio includes vaccines for breast and ovarian cancer, as well as additional vaccines targeting other cancers, developed in collaboration with Cleveland Clinic [4]

Core Insights - Anixa Biosciences has received a patent for its breast cancer vaccine technology in China, extending intellectual property protection until 2040, which enhances its global patent portfolio and supports future commercialization strategies [1][3]. Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes a breast cancer vaccine developed in collaboration with Cleveland Clinic [5]. Vaccine Technology - The breast cancer vaccine targets human-lactalbumin, a protein linked to lactation that is abnormally expressed in certain breast cancers, aiming to prime the immune system to prevent tumor formation without damaging normal tissue [2][4]. Clinical Development - A Phase 1 clinical trial for the breast cancer vaccine has been completed, with full results to be presented at the San Antonio Breast Cancer Symposium on December 11, 2025 [4]. Intellectual Property Strategy - The newly issued patent reinforces Anixa's intellectual property strategy, allowing for broader international development and commercialization opportunities in regions with high breast cancer incidence [3][4].

Core Insights - Anixa Biosciences has initiated the transfer of the Investigational New Drug (IND) application for its breast cancer vaccine, which is currently held by Cleveland Clinic, to advance to a Phase 2 clinical trial [1][2][4] - The Phase 1 clinical trial has shown promising results, with over 70% of patients exhibiting immune responses, indicating the vaccine's potential effectiveness [2][4] - The breast cancer vaccine targets α-lactalbumin, a protein associated with lactation that re-emerges in many breast cancer forms, suggesting both therapeutic and preventive benefits [3][4] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is developing vaccines for breast and ovarian cancer, as well as other cancers, utilizing technologies that target proteins expressed in certain cancer forms [5] - Anixa's business model involves partnerships with leading research institutions to explore and commercialize emerging technologies in cancer treatment [5]

Core Insights - Anixa Biosciences has received a Notice of Allowance for a new patent in Canada related to its breast cancer vaccine technology, enhancing its international intellectual property portfolio [1][2][3] - The patent provides composition-of-matter protection for Anixa's immunogenic approach to breast cancer prevention and treatment, which is exclusively licensed from Cleveland Clinic [1][4] - Breast cancer is the most commonly diagnosed cancer in women globally, accounting for approximately 25% of new cancer cases in women in Canada and 13% of female cancer deaths annually [3] Intellectual Property Expansion - The newly allowed Canadian patent complements existing and pending patents in the United States and other key global jurisdictions, reinforcing Anixa's leadership in cancer immunoprevention [2][5] - This expansion of the patent estate is crucial for future regulatory and commercial efforts outside the U.S., positioning the company for strategic global opportunities [2][3] Vaccine Technology - Anixa's breast cancer vaccine targets human α-lactalbumin, a protein aberrantly expressed in certain breast cancers, aiming to prime the immune system to prevent tumor formation while sparing normal tissue [4][5] - The company's broader vaccine platform also addresses other high-incidence cancers, transforming the approach to cancer prevention in the medical community [5] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [6] - The company partners with renowned research institutions to develop vaccines targeting various cancers, including breast and ovarian cancer, utilizing a unique business model that allows for continuous examination of emerging technologies [6]

Core Viewpoint - Anixa Biosciences has announced the issuance of a key patent for its ovarian cancer vaccine technology, which is expected to enhance the company's position in the cancer treatment market [1][4]. Group 1: Patent and Technology - The United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025, covering methods related to eliciting an immune response targeting anti-Müllerian hormone receptor, type II (AMHR2) [1]. - The patent includes methods for administering an immunogenic composition that encodes the AMHR2 polypeptide, specifically targeting the extracellular domain of human AMHR2 [3]. - Anixa holds exclusive worldwide rights to the patent, which was issued to Cleveland Clinic [3]. Group 2: Collaboration and Development - The ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute, focusing on high-risk populations such as those with BRCA mutations [2]. - Anixa's therapeutic portfolio includes an ovarian cancer immunotherapy program utilizing chimeric endocrine receptor-T cell (CER-T) technology, which is distinct from traditional CAR-T therapies [4]. - The company is also developing additional cancer vaccines in collaboration with Cleveland Clinic to address various cancers, including breast, lung, colon, and prostate cancers [4].

Core Insights - Anixa Biosciences has initiated dosing for the first patient in the fourth dosage cohort of its Phase 1 clinical trial for CAR-T therapy targeting recurrent ovarian cancer, marking a significant advancement in the study [1][2] - The fourth cohort will receive a dose of three million CAR-positive cells per kilogram, which is thirty times higher than the initial cohort dose, indicating a strategic escalation in dosage to assess safety and efficacy [2][4] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a specific emphasis on ovarian cancer immunotherapy developed in collaboration with Moffitt Cancer Center [4] - The company's CAR-T technology targets the follicle-stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells and certain cancer cells, positioning it uniquely in the oncology landscape [3][4] - Anixa's business model involves partnerships with leading research institutions, allowing for the exploration of emerging technologies in cancer treatment [4]

Core Viewpoint - Anixa Biosciences, Inc. is set to host an investor webcast on June 26, 2025, to discuss its business strategy, therapeutic portfolio, market opportunities, and upcoming milestones [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention [4]. - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [4]. - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [4]. - The company partners with renowned research institutions to explore emerging technologies for development and commercialization [4]. Webcast Details - The webcast will feature an introductory presentation by Dr. Amit Kumar, Anixa's Chairman and CEO, followed by a Q&A session for investors [2]. - Interested participants must pre-register to listen to the webcast and ask questions during the live event [3].

Core Points - Anixa Biosciences has received a Notice of Allowance for a new patent related to its breast cancer vaccine technology, which broadens the scope of immunogenic compositions used in the vaccine [1][2] - The patent covers methods of immunizing patients against breast cancer using an immunogenic composition containing the human α-lactalbumin protein, which is expressed in certain breast cancers [2] - The CEO of Anixa highlighted that this patent enhances the company's intellectual property portfolio, which includes multiple issued and pending patents in the U.S. and internationally [3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [3] - The company's vaccine portfolio includes vaccines for breast and ovarian cancer, as well as other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [3] - Anixa's business model involves partnerships with renowned research institutions, allowing the company to explore emerging technologies for further development and commercialization [3]